Vasoactive intestinal peptide

Relief Therapeutics to Participate in Industry and Investor Conferences in May

Retrieved on: 
Monday, May 9, 2022

Geneva, Switzerland, May 9, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following industry and investor conferences in May.

Key Points: 
  • Geneva, Switzerland, May 9, 2022 RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following industry and investor conferences in May.
  • Jack Weinstein, Chief Financial Officer and Treasurer of Relief will present a company overview on May 17 at 2:30 p.m. CEST, in Milan, Italy.
  • The Bioquity Europe one-on-one partnering platform enables partners and investors to schedule virtual meetings.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea

Retrieved on: 
Wednesday, May 4, 2022

Furthermore, T4 strongly establishes its role as an adjunctive treatment for diabetic corneal impediments with no side effects, thereby easing the disadvantages of present methods of [eye] care," according to the research team.

Key Points: 
  • Furthermore, T4 strongly establishes its role as an adjunctive treatment for diabetic corneal impediments with no side effects, thereby easing the disadvantages of present methods of [eye] care," according to the research team.
  • The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
  • RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
  • The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock

Retrieved on: 
Wednesday, February 2, 2022

"Relief's suite of commercial stage biopharmaceuticals, along with an impressive product pipeline and highly focused growth strategy, was instrumental in my decision to join the company's Board," noted Ms.

Key Points: 
  • "Relief's suite of commercial stage biopharmaceuticals, along with an impressive product pipeline and highly focused growth strategy, was instrumental in my decision to join the company's Board," noted Ms.
  • "I am delighted to contribute my insights and experience to Relief to help management achieve its U.S. and international commercialization goals at this pivotal time in the company's history."
  • Lock earned a degree in Science/Nursing at Royal Melbourne University, Australia and studied General Management and Internal General Management at CEDEP, France.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.

NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments

Retrieved on: 
Tuesday, January 18, 2022

RADNOR, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) today announced enhancements to its Expanded Access and Right to Try programs.

Key Points: 
  • RADNOR, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP) today announced enhancements to its Expanded Access and Right to Try programs.
  • This expansion comes as supplies of ZYESAMI have increased through the partnership between NRx and Nephron Pharmaceuticals, which is manufacturing ZYESAMI at commercial scale.
  • Detailed data on results seen in clinical trials of ZYESAMI (Aviptadil) may be viewed on the NRx website ( https://www.nrxpharma.com/right-to-try/ ).
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.

EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January

Retrieved on: 
Wednesday, January 5, 2022

Geneva, Switzerland, January 5, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following virtual investor conferences in January.

Key Points: 
  • Geneva, Switzerland, January 5, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following virtual investor conferences in January.
  • Jack Weinstein, Chief Financial Officer and Treasurer of Relief, will present a company overview at the conference.
  • Mr. Weinstein will present a corporate overview of Relief which can be viewed on demand throughout the conference.
  • RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY.

PhaseBio Provides Pemziviptadil (PB1046) Program Update

Retrieved on: 
Tuesday, December 21, 2021

Upon completion of the final analyses of the pemziviptadil trial, we will evaluate the potential for a future trial of pemziviptadil.

Key Points: 
  • Upon completion of the final analyses of the pemziviptadil trial, we will evaluate the potential for a future trial of pemziviptadil.
  • We continue to believe pemziviptadil is a potentially valuable asset for the treatment of pulmonary arterial hypertension and other diseases.
  • Pemziviptadil, a novel, subcutaneously injected VIP analogue, is a recombinant fusion protein composed of VIP and PhaseBios proprietary elastin-like polypeptide (ELP) biopolymer.
  • These forward-looking statements speak only as of the date hereof, and PhaseBio Pharmaceuticals, Inc. disclaims any obligation to update these statements except as may be required by law.

Relief Therapeutics to Webcast Live at Life Sciences Investor Forum on December 16th

Retrieved on: 
Friday, December 10, 2021

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

Key Points: 
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.
  • A real-time solution for investor engagement, Life Sciences Investor Forum is part of the OTC Market Group's suite of investor relations services specifically designed for more efficient investor access.
  • Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

NRx Pharmaceuticals Announces Progress on Worldwide Commercial Scale Development of ZYESAMI™ (aviptadil)

Retrieved on: 
Tuesday, October 12, 2021

This module will now be used as part of the FDA's rolling review process supporting the New Drug Application for ZYESAMI.

Key Points: 
  • This module will now be used as part of the FDA's rolling review process supporting the New Drug Application for ZYESAMI.
  • NRx awaits a QP Declaration that is required by the EU regulatory authorities for the release of ZYESAMI.
  • The audit was completed in preparation for submission of European Union (EU)-standard ZYESAMI to EU and United Kingdom health regulatory authorities.
  • NRx Pharmaceuticals (NRx) draws upon more than 300 years of collective, scientific, and drug-development experience to bring improved health to patients.

EQS-News: Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 8, 2021

Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

Key Points: 
  • Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
    Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
    Geneva, Switzerland, September 8, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that Jack Weinstein, Relief's Chief Financial Officer and Treasurer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021.
  • The on-demand presentation will be available beginning September 13, at 7:00am ET on the Relief website at: https://www.relieftherapeutics.com/news-and-events and will be archived for a period of 90 days after the conference.
  • Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company.
  • RELIEF THERAPEUTICS Holding AGis listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.

EQS-News: Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19

Retrieved on: 
Tuesday, August 31, 2021

According to the press release, the new analysis shows that patients treated with ZYESAMI demonstrated improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment.

Key Points: 
  • According to the press release, the new analysis shows that patients treated with ZYESAMI demonstrated improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment.
  • This latest analysis also appears to support NRx's plan to submit an application for Breakthrough Therapy Designation to the U.S. Food and Drug Administration for this indication.
  • Relief believes that, if granted, this could confer Priority Review to the aviptadil New Drug Application, when submitted.
  • Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale.